Abstract:OBJECTIVE:To develop a HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and investigate its immunological features.METHODS:Thirty-two CB17SCID mice were randomly divided into 4 groups: group A (5 mice) subcutaneously injected with phosphate-buffered saline, group B (5 mice) intraperitoneally injected with human peripheral blood lymphocyte (PBL) for immune reconstruction, group C (11 mice) subcutaneously injected with human cervical carcinoma cell line SiHa, and group D (11 mice) intraperitoneally injected with PBL and subcutaneously injected with SiHa cells after 24 hours of PBL transplantation. The tumor growth, behaviors and status of xenogeneic graft versus host disease (XGVHD) were observed. Human immunoglobulins G (IgG) in mouse serum, the percentage of human CD3(+), CD4(+) and CD8(+) T cells in peripheral blood and spleen, spleen weight, tumor infiltrating lymphocytes and human CD4(+) T cells, and cytotoxicity test of spleen cells were detected.RESULTS:The rate of successful tumor transplantation was 100%. XGVHD was not found. On the 5th day, human IgG level in the group B (0.98 microg/ml +/- 0.20 microg/ml) and group D (1.39 microg/ml +/- 0.25 microg/ml) was significantly higher than that in the group A (t = 7.655, 9.937, both P = 0.000). Human IgG level in group D was significantly higher than that in the group B (t = 3.200, P = 0.006). Only very low levels of human serumal IgG were detected in the group C and group A with no significantly difference. The level of human serumal IgG was gradually elevated in all the humanized SCID mice as the the time after PBL transplantation went on, and was significantly higher than that in non-humanized mice (P < 0.05). The percentage of human CD3(+), CD4(+) and CD8(+) T cells was significantly increased in the peripheral blood and spleen of immunoreconstituted SCID mice. The weight of spleen was markedly increased in the group D. TIL infiltrating in the tumor were remarkable and human CD4(+) T cells was detected by immunohistochemistry in the group D but not in the group C. The spleen cells in the group D displayed stronger cytotoxicity to the target cells (P < 0.05).CONCLUSION:Human immune function can be successfully reconstructed in SCID mouse via intraperitoneally injecting with human PBL, and induce anti-tumor immune response to the transplantated tumor of HPV16 positive cervical cancer.

Biological features of the mouse HL-60 leukemia models constructed by different inoculation methods

Protocol to establish a stable MLL-AF9_AML mouse model.

[Model of B Immunoblastic Lymphomas in the Hu-PBL-SCID Mice].

Establishment of DsRed-labled leukemia mouse model

Establishment of animal model with B lineage acute leukemia in nude mice for evaluation of new therapeutic agents]

Esablishment of Human Lung Cancer Model in the Scid Mouse

[Establishment of K562/NOD-SCID Mouse Model with Leukemia].

Establishment of K562/NOD-SCID mouse model with leukemia]

Establishment of Human Acute Monocytic Leukemia Model in Severe Combined Immunodeficient (SCID) Mice and the Analysis of Pathological Changes

[Development of HPV16 Positive Cervical Cancer Model in the Hu-Pbl-scid Mouse and Its Immunological Features].

[Study on Tumorigenic Mechanism of Human Leukemia Cell Line in Nude Mice].

Establishment of a Disseminated Model of Mouse B Lymphoma

Establishment of Mouse Model with Humanized Chronic Myeloid Leukemia

Establishment of a Cervical Cancer Model Via Inoculating SiHa Cells into Humanized Severe Combined Immunodeficient Mice.

Construction of A20 Mouse B Lymphoma Animal Model in Different Ways

[Establishment of Orthotopic Lewis Lung Cancer Model in Mouse].

Comparison of Orthotopically Implanted Mouse Models of Primary Breast Cancer Established by Different Methods

Experimental Study on Non-myeloablative Allogeneic Bone Marrow Transplantation for Treatment of Leukemia Mice

[A Human Bone Marrow Cell Line (B3HM) Inducing Leukemia in Mouse].

Establishment of Human Acute Monocyte Leukemia Model with Systemic Leukemia in Npg Mice

Establishment of Mouse Model of Nonmyeloablative Bone Marrow Transplantation